A Phase 1, Randomized, Controlled, Double-blind, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of AERAS-422 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 15 Aug 2012
At a glance
- Drugs AERAS 422; BCG
- Indications Tuberculosis
- Focus Adverse reactions
- 15 Aug 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Apr 2011 New trial record